Gamida Cell Ltd. (NASDAQ:GMDA) announced that the first patient has received a stem cell transplant with Omisirge, the only allogeneic stem cell therapy approved by the FDA. The company has exceeded its 2023 launch goals, with 15 transplant centers onboarded across the US and confirmed coverage with payers that cover 90% of commercial lives. Gamida Cell is actively engaged with more than 90% of the top 70 transplant centers, which conduct approximately 80% of transplants. The company plans to expand its team from four to eight account managers by the start of 2024.